AT
This biotech company develops RNA Aptamer-based therapeutics for cancer treatment, utilizing a platform that links Aptamers to small RNA molecules and chemotherapeutic agents. By targeting specific tumors, the technology aims to enhance treatment efficacy while minimizing side effects for patients.
Updated 20 months ago
Funding
$2.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
AP
Funding rounds are not available yet.
Founders
Product
Features
- This biotech company develops RNA Aptamer-based therapeutics for cancer treatment, utilizing a platform that links Aptamers to small RNA molecules and chemotherapeutic agents. By targeting specific tumors, the technology aims to enhance treatment efficacy while minimizing side effects for patients.